CompletedNot Applicable

Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates

385 participantsStarted 2010-01-01

Plain-language summary

This study aimed to assess the prevalence of upgrade to invasive breast cancer and axillary lymph node metastasis in patients who were diagnosed with DCIS on biopsy and subsequently underwent mastectomy with axillary surgery to establish the need for SLNB. Furthermore, we explored the clinicopathologic features related to the upgrade to invasive breast cancer and axillary lymph node metastasis.

Who can participate

Age range19 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Women diagnosed with DCIS in preoperative biopsy samples obtained by core needle biopsy, vacuum-assisted breast biopsy, or excisional biopsy
✓. Women underwent curative surgery for DCIS

Exclusion criteria

✕. Patients who received breast-conserving surgery
✕. Patients who had concurrent contralateral invasive breast cancer
✕. Patients who were in case of ipsilateral breast tumor recurrence
✕. Patients whose invasiveness was uncertain in the biopsy samples

What they're measuring

Axillary lymph node metastasis rate

Timeframe: up to 2 weeks after surgery

Trial details

NCT IDNCT05961280

SponsorGangnam Severance Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-12-30

View on ClinicalTrials.gov More Ductal Carcinoma in Situ trials